Vous avez cherché: progenitor (Anglais - Danois)

progenitor cell
progenitorcelle

progenitor genetic element
udgangsgenelement

assessment of progenitor cell yields
vurdering af stamcellehøst

mobilisation of peripheral blood progenitor cells (pbpc)
mobilisering af perifere blodprogenitorceller (pbpc)

in peripheral blood progenitor cell mobilisation in normal donors
ved mobilisering af perifere blodstamceller hos raske donorer

mobilisation of peripheral blood progenitor cells (pbpcs).
mobilisering af perifere blodstamceller (pbpc’er).

special precautions in patients undergoing peripheral blood progenitor cell mobilisation
særlige forsigtighedsregler hos patienter, der får foretaget mobilisering af perifere blodstamceller

alemtuzumab does not appear to damage haematopoietic stem cells or progenitor cells.
alemtuzumab synes ikke at ødelægge hæmatopoietiske stamceller eller progenitorceller.

there is no known antidote to busilvex other than haematopoietic progenitor cell transplantation.
der kendes ingen antidot til busilvex bortset fra transplantation af hæmatopoietiske progenitorceller.

busilvex is administered prior the conventional haematopoietic progenitor cell transplantation (hpct).
busilvex administreres før konventionel transplantation af hæmatopoietiske progenitorceller (hpct).

biograstim is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).
biograstim er indiceret til mobilisering af perifere blodstamceller (pbpc).

accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).
accofil er indiceret til mobilisering af perifere blodprogenitorceller (pbpc).

some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool and may adversely affect progenitor mobilisation.
visse cytostatika udviser især toksicitet over for de hæmatopoietiske stamceller og kan påvirke mobilisering af stamceller negativt.

use of filgrastim, either alone or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood.
brug af filgrastim alene eller efter kemoterapi mobiliserer hæmatopoietiske stamceller til perifert blod.

busilvex has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells.
busilvex er blevet undersøgt hos patienter, hovedsagelig med blodkræft, som havde behov for transplantation af bloddannende progenitorceller.

an m2 bone marrow (≥ 5% and ≤ 25% blasts) and appearance of normal progenitor cells
m2- knoglemarv (≥ 5% og ≤ 25% blaster) – udseende som for normale progenitorceller

an m2 bone marrow ( 5% and ≤ 25% blasts) and appearance of normal progenitor cells
m2-knoglemarv ( 5 % og ≤ 25 % blaster) – udseende som for normale progenitorceller

as a ‘conditioning’ (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells).
som "konditionerende behandling" (forberedelsesbehandling) inden transplantation af knoglemarvsceller (de celler, der producerer blodlegemer).